Synairgen’s inhalable drug fails study in hospitalized COVID-19 patients, shares plummet
Synairgen’s inhalable therapy has failed in late-stage trial testing in patients hospitalized with COVID-19, wiping out over 85 per cent of the British drugmaker’s stock value on Monday after the …
Read More